Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique
Journal of Global Oncology · 2019-12 · (5) · 1-9
DOI: 10.1200/jgo.19.00172 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Global Oncology, 2019-12. Verfasst von Gabrielle C Bouda und 9 weiteren Autor:innen. Beteiligte Einrichtung: CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE To evaluate the results of an intensive polychemotherapy regimen for Burkitt lymphoma (BL) in sub-Saharan African pediatric centers. PATIENTS AND METHODS Children with advanced-stage BL (stages II bulky, III, and IV) treated with the GFAOP–Lymphomes Malins B (GFALMB) 2009 protocol in 7 centers between April 2009 and September 2015 were prospectively registered. Treatment regimen contained a prephase with cyclophosphamide followed by 2 induction courses (cyclophosphamide, vincristine, prednisone, high-dose methotrexate [HDMTX]), 2 consolidation courses (cytarabine, HDMTX), and a maintenance phase only for stage IV. HDMTX was given at the dose of 3 g/m 2 . RESULTS Four hundred patients were analyzed: 7% had stage II bulky, 76% stage III, and 17% stage IV disease. Median age was 7.3 years, and sex ratio was 1.9:1 (male:female). A total of 221 patients received the whole protocol treatment and 195 achieved complete remission (CR), 11 of them after a second-line treatment. Treatment abandonment rate was 22%. One hundred twenty-five patients died, of whom 49 deaths were related to treatment toxicity. A total of 275 patients are alive, including 25 despite treatment abandonment, but only 110 are known to be in CR with a follow-up > 1 year, indicating a high rate of loss to follow-up. Twelve-month overall survival (OS) was 60% (95% CI, 54% to 66%) and 63%, 60%, and 31%, respectively, for stage II bulky, III, and IV. Patients with stage III disease who started second induction course within 34 days had OS of 76%, versus 57% ( P = .0062) beyond 34 days. CONCLUSION The GFA-LMB2009 protocol improved patients’ survival. Early dose intensity of treatment is a strong prognostic factor. Improving supportive care and decreasing loss to follow-up are crucial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CHU Yalgado Ouédraogo, Ouagadougou, Burkina Faso.
- CHU Gabriel Touré, Bamako, Mali.
- CHU de Treichville, Abidjan, Côte d'Ivoire.
- Gustave Roussy Hospital and GFAOP Database Center, Villejuif, France.
- CHU Sylvanus Olympio, Lomé, Togo.
- Centre Mère-Enfant, Fondation Chantal Biya, Yaoundé, Cameroun.
Zitieren
APA
Bouda, G. C., Traoré, F., Couitchere, L., Raquin, M. A., Guedenon, K. M., Pondy, A., Moreira, C., Rakotomahefa, M., Harif, M., & Patte, C. (2019). Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique. Journal of Global Oncology, 1-9. https://doi.org/10.1200/jgo.19.00172
Vancouver
Bouda GC, Traoré F, Couitchere L, Raquin MA, Guedenon KM, Pondy A, et al. Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique. Journal of Global Oncology. 2019:1-9. doi:10.1200/jgo.19.00172
BibTeX
@article{Bouda2019,
author = {Bouda, Gabrielle C and Traoré, Fousseyni and Couitchere, Line and Raquin, Marie-Anne and Guedenon, Koffi M and Pondy, Angele and Moreira, Claude and Rakotomahefa, Mbola and Harif, Mhamed and Patte, Catherine},
title = {Advanced Burkitt Lymphoma in Sub-Saharan Africa Pediatric Units: Results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pédiatrique},
journal = {Journal of Global Oncology},
year = {2019},
number = {5},
pages = {1--9},
doi = {10.1200/jgo.19.00172}
}
EUVIMED